Determination of favipiravir in human plasma using homogeneous liquid–liquid microextraction followed by HPLC/UV

Bioanalysis ◽  
2022 ◽  
Author(s):  
Inas A Abdallah ◽  
Sherin F Hammad ◽  
Alaa Bedair ◽  
Ahmed H Elshafeey ◽  
Fotouh R Mansour
Keyword(s):  
Human Plasma ◽  
Correlation Coefficient ◽  
Antiviral Drug ◽  
Homogeneous Liquid ◽  
The Us ◽  
Us Fda ◽  
Optimum Extraction ◽  
Separating Agent ◽  
Liquid Microextraction

Background: Favipiravir is an antiviral drug that was recently approved for the management of COVID-19 infection. Aim: This work aimed to develop a new method, using sugaring-out induced homogeneous liquid–liquid microextraction followed by HPLC/UV for the determination of favipiravir in human plasma. Materials & methods: The optimum extraction conditions were attained using 500 μl of tetrahydrofuran as an extractant and 1400 mg of fructose as a phase-separating agent. Results: The developed method was validated according to the US FDA bioanalytical guidelines and was found linear in the range of 25-80,000 ng/ml with a correlation coefficient of 0.999. Conclusion: These results showed that the developed method was simple, easy, valid and adequately sensitive for determination of favipiravir in plasma for bioequivalence studies.

Development and validation of a UPLC–MS/MS method for simultaneous determination of LBPT and its metabolites in human plasma

Bioanalysis ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 211-220
Author(s):  
Mengyi Wu ◽  
Aijing Liu ◽  
Quankun Zhuang ◽  
Ranran Jia ◽  
Yinping Zhou ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Human Plasma ◽  
Tandem Mass ◽  
Plasma Samples ◽  
Triple Quadrupole ◽  
Multiple Reactions ◽  
The Us ◽  
Us Fda ◽  
Development And Validation

Aim: A UPLC–MS/MS method was developed to determine LBPT as well as its four metabolites in human plasma to support the clinical study aiming to evaluate the efficacy of LBPT tablet in patients undergoing hip/knee replacement. Methodology: Plasma samples were prepared by protein precipitation and then separated on a C18 analytical column using (A) acetonitrile (B) 0.1% formic acid and 10 mM ammonium formate in water. The detection was performed on a triple quadrupole tandem mass spectrometer in positive electrospray ionization using multiple reactions monitoring mode. Results & conclusion: The method has been validated in accordance with the US FDA guidelines and was applied to the measurement of five analytes in human plasma samples from a Phase II clinical trial.

Developing an isotope dilution UHPLC–MS/MS method to quantify linezolid in human plasma: application to therapeutic drug monitoring

Bioanalysis ◽  
2020 ◽  
Vol 12 (14) ◽  
pp. 991-1001
Author(s):  
Yanping Guan ◽  
Xiaoxia Yu ◽  
Ying Wang ◽  
Qinhai Li ◽  
Dan Liang ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Human Plasma ◽  
Drug Monitoring ◽  
Drug Exposure ◽  
Therapeutic Drug ◽  
The Us ◽  
Dosing Regimens ◽  
Us Fda ◽  
Isocratic Mode

Aim: To optimize clinical efficacy and reduce the drug-exposure-related toxicity of linezolid, whose concentrations show wide inter-variabilities, a simple and reliable quantitative assay for therapeutic drug monitoring is necessary. Results: A UHPLC–MS/MS assay has been established for determination of linezolid in human plasma and fully validated according to the US FDA guidelines. After a simple, isotope-dilluted precipitation with methanol, the analytes were separated by a straightforward isocratic mode and the MS/MS was conducted under the ESI+ mode fitted with SRM. The calibration curves proved acceptable linearity in the range of 0.1–30.0 µg/ml. Conclusion: The present assay is currently used in routine clinical practice, being applied to therapeutic drug monitoring and helps to optimize individual dosing regimens and manage adverse effects in ICU patients.

An HPLC method for simultaneous quantification of sunitinib and its active metabolite, SU12662, using hydrophilic interaction chromatography principle

Bioanalysis ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 75-85 ◽  
Author(s):  
Murari Gurjar ◽  
Parsshava Mehta ◽  
Jyoti Sharma ◽  
Sneha Patil ◽  
Preeti Kulkarni ◽  
...  
Keyword(s):  
Human Plasma ◽  
Active Metabolite ◽  
Internal Standard ◽  
Hplc Method ◽  
Therapeutic Drug ◽  
Hydrophilic Interaction ◽  
Reliable Determination ◽  
The Us ◽  
Us Fda

Aim: To develop a sensitive HPLC method for the quantitation of sunitinib (SU) and its active metabolite N-desethyl-sunitinib (SU12662) in human plasma. Materials & methods: The analytes were extracted from 500 μl of plasma using liquid–liquid extraction followed by protein precipitation. Chromatographic separation of two analytes and internal standard, vandetenib, was achieved on a hydrophilic interaction liquid chromatography analytical column using a gradient program. Calibration curves were linear over the range of 10–250 ng/ml for both SU and SU12662. The method was validated according to the US FDA guidelines for bioanalytical methods. Accuracy of the method at 10 ng/ml for SU and SU12662 was 8.7 and 6.7%, respectively, and precision was 10.18% and 17.3%, respectively. Conclusion: This method allows a specific, sensitive and reliable determination of SU and SU12662 in human plasma in a single analytical run which makes it useful for therapeutic drug monitoring.

In‐process prepared deep eutectic solvent based homogeneous liquid–liquid microextraction for the determination of irgaphos 168 and irganox 1010 in polypropylene packed drinks

2020 ◽  
Vol 43 (14) ◽  
pp. 2850-2857
Author(s):  
Maryam Naebi ◽  
Masoumeh Arabli Jamshidi ◽  
Mir Ali Farajzadeh ◽  
Jafar Abolhassni ◽  
Mohammad Reza Afshar Mogaddam
Keyword(s):  
Deep Eutectic Solvent ◽  
Irganox 1010 ◽  
Homogeneous Liquid ◽  
Liquid Microextraction

The first method for determination of lipoyllysine in human urine after oral lipoic acid supplementation

Bioanalysis ◽  
2019 ◽  
Vol 11 (14) ◽  
pp. 1359-1373 ◽  
Author(s):  
Adrianna Kamińska ◽  
Iwona E Głowacka ◽  
Beata Pasternak ◽  
Rafał Głowacki ◽  
Grażyna Chwatko
Keyword(s):  
Acetic Acid ◽  
Lipoic Acid ◽  
Human Urine ◽  
Mobile Phase ◽  
Thiol Group ◽  
Bioanalytical Method ◽  
The Us ◽  
Us Fda ◽  
Reduced Forms

Aim: The first method on urinary excreted amounts of lipoyllysine (LLys) after lipoic acid (LA) supplementation was developed and validated. The suggested procedure allowed simultaneous determination of LLys and LA. Methodology & results: After the conversion of analytes into their reduced forms with tris(2-carboxyethyl)phosphine and derivatization via thiol group with 1-benzyl-2-chloropyridinium bromide, separation of analytes derivatives was performed on C18 column using a gradient mobile phase consisting of acetic acid and acetonitrile. The calibration curves for LA and LLys were linear (R2 > 0.999) in the range of 0.4–12 μM concentration and all validation results were acceptable, according to the US FDA bioanalytical method guidelines. Conclusion: This method was effectively applied for LA and LLys quantification in human urine after oral LA supplementation.

Sign in / Sign up

Export Citation Format

Share Document